Loading
Life sciences · Journal article
Onco · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
PROTACs represent a cutting-edge approach to the discovery of innovative cancer therapies. By exploiting the cell’s ubiquitin–proteasome system, PROTACs induce the selective degradation of target proteins, providing a distinct advantage over conventional inhibitors that only block protein function. This review delves into the design principles and mechanisms underlying PROTACs, emphasizing their potential to circumvent drug resistance and achieve prolonged therapeutic effects. Recent advancements have focused on enhancing the specificity, bioavailability, and overall efficacy of PROTACs, demonstrating promising results in preclinical cancer models. The ability of PROTACs to target previously “undruggable” proteins opens new avenues for cancer treatment, offering the potential for more effective and personalized therapeutic strategies. As research continues to evolve, the optimization and clinical translation of PROTACs could declare a new era in oncology, revolutionizing the landscape of cancer drug discovery and personalized medicine.